Dr. Marc Gurwith
PaxVax, Inc., USA
Chief Medical Officer
Email: mgurwith@paxvax.com, mjgurwith@gmail.com
Qualifications
1991 J.D., Temple University School of Law, Law
1965 M.D., Harvard Medical School, Medicine
1961 B.A., Yale University, Philosophy
Publications (selected)
-
Kennedy JS, Gurwith M, Dekker C, Frey SE, Edwards KM, Kenner J, Lock M, Empig, C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg, RN Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naïve Adults. J Infect Dis 2011. 204 (10): 1395-1402.
-
Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P,. Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC. Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine (AIDSVAX B/B). J Infect Dis. 2010 202(4):595-605.
-
Jones N, DeCamp A, Gilbert P, Peterson, M, Gurwith M, Cao H. AIDSVAX Immunization Induces HIV-specific CD8+ T-cell Responses in High-risk, HIV-negative Volunteers Who Subsequently Acquire HIV Infection. Vaccine, 2009. 27(7):1136-40.
-
Kittikraisak W, van Griensven F, Martin M, McNicholl J, Gilbert PB, Chuachoowong R, Vanichseni S, Sutthent R, Tappero JW, Mastro TD, Hu DJ, Gurwith M, Kitayaporn D, Sangkum U, Choopanya K. Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr, 2009. 51(5):601-8.
-
Schneider JA, Alam SA, Ackers M, Parekh B, Chen HY, Graham P, Gurwith M, Mayer K, Novak RM, Mucosal HIV Binding Antibody and Neutralizing Activity among High-Risk HIV Uninfected Female HIV Vaccine Trial Participants. J Infect Dis. 2007 196(11):1637-44.
-
Cummins J, Denniston M, Mayer KH, Pickard R, Novak RM, Graham P, Gurwith M, OrelindK,. Ackers ML, Dezzutti1 CS. Mucosal Innate Immune Factors in Secretions from High Risk Individuals Immunized with a Bivalent gp120 Vaccine. AIDS Res Hum Retroviruses. AIDS Res Hum Retroviruses 2007 23(5):748-54.
-
Kenner JR, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: An attenuated smallpox vaccine. Vaccine 2006 24(47-48):7009-22.
-
McFarland EJ, Johnson DC, Meresan P, Fenton T, Tomaras GD, McNamara J, Douglas SD, Read JS, Deville J, Gurwith M, Gurunathan S, Lambert JS. HIV-1 Vaccine Induced Immune Responses in Newborns of HIV-1 Infected Mothers. AIDS 2006 20(11):1481-9.
-
Gorse GJ, Keitel W, Keyserling H, Taylor DN; Lock M, Alves K, Kenner J, Deans L, Gurwith M. Immunogenicity and Tolerance of Ascending Doses of a Recombinant Protective Antigen (rPA102) Anthrax Vaccine: a Randomized, Double-Blinded, Controlled, Multicenter Trial. Vaccine 2006 24(33-34):5950-9.
-
Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine. 2006 24(17):3686-94.
-
McDougal JS, Parekh BS, Peterson ML, Branson BM, Dobbs T, Ackers M, Gurwith M. Comparison of HIV Type 1 Incidence Observed during Longitudinal Follow-Up with Incidence Estimated by Cross-Sectional Analysis Using the BED Capture Enzyme Immunoassay. AIDS Res Hum Retroviruses. 2006 22(10):945-52.
-
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661-71.
-
Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial. J Infect Dis 2005;191:666-77.
-
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, Gilbert PB, Hudgens MG, Metch BJ, Self SG, Berman PW, Francis DP, Gurwith M, Heyward WL, Jobes DV, Peterson ML, Popovic V, Sinangil FM. Placebo-Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 Infection. J Infect Dis 2005;191:654-65.
-
Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1-Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine. J Infect Dis 2005;192:974-983.
Profile Details
NULL